[WIRB - IAA] A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to determine the safety and side effects, good and/or bad, of each combination of study drugs.
Another purpose of the study is to measure the effects of the study drug, its mechanism of action on tumor cells and determine how the body processes and gets rid of the study drug.
Metastatic castration resistant prostate cancer (mCRPC)
-Subjects should have metastatic castration resistant prostate cancer
-Subjects should have at least one prior treatment with an FDA approved androgen-signaling inhibitor therapy (eg, abiraterone, enzalutamide, apalutamide) in the castration-resistant setting
-Subjects should be willing to have a research tumor biopsy (if medically feasible)
18 - NA
Healthy Volunteers Needed
Duration of Participation
Participants will receive the investigational drugs for up to 2 years. There will be one follow up visit 30 days after the last dose of the study drugs. After discontinuation of the study drugs, participants will be contacted by phone every 3 months. Participants will be followed for up to 2.5 years from the beginning of study participation.
Clinical Trials Information Line: Phone 503-494-1080 or firstname.lastname@example.org
Parker Institute for Cancer Immunotherapy